Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 216

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 216
---
 a private biotechnology company focused on the research and development of therapeutics that are informed by a deep understanding of the
biological processes of gut microbial populations and the pathways by which they influence our health and well-being. Dr. Zhao holds a bachelor’s degree in biology from Peking University and Ph.D. from the College of Pharmacy at the
University of Texas at Austin. He completed his postdoctoral fellowship at the State University of New York at Buffalo. The Board believes that Dr. Zhao is qualified to serve as a director of the Company because of his extensive industry
background and experience in drug development.

Anupam Dalal, M.D.,has served on the board of directors of Aadi (formerly known as Aerpio
Pharmaceuticals, Inc. through August 2021) since November 2011. Since August 2016, Dr. Dalal has been working at Acuta Capital Partners, LLC, a financial investment firm. From 2006 to 2016, Dr. Dalal was the Managing Director of Kearny
Venture Partners, a healthcare investment firm. He was a Founder and Managing Member of KVP Capital, an investment fund. He served as a director of Akebia Therapeutics from 2008 to 2016. Dr. Dalal received an M.D. from the University of
California in San Francisco with honors; an M.B.A., with distinction, from Harvard Business School; and a B.A. in Economics, Phi Beta Kappa and highest honors, from the University of California at Berkeley. We believe that Dr. Dalal is
qualified to serve as a director based on his industry experience.

Karin Hehenberger, M.D., Ph.D.,has served on Aadi’s board of
directors since August 2021. From January 2014 to March 2024, Dr. Hehenberger served as Chief Executive Officer of Lyfebulb, Inc. (“Lyfebulb”), a patient engagement platform; following Lyfebulb’s acquisition by Patient Care
America (“PCA”) in March 2024, Dr. Hehenberger became Chief Medical Officer of PCA and Chief Medical Officer of Lyfebulb, a Patient Care America company. From 2011 to 2013, Dr. Hehenberger served in various roles at Coronado
Biosciences, Inc. (now Fortress Biotech, Inc.), including Senior Vice President of Scientific Affairs and Chief Medical Officer. Dr. Hehenberger has previously